QLS5316 / Qilu Pharma - LARVOL DELTA

First in Human Study of QLS5316 in Solid Tumors (clinicaltrials.gov) - P1 | N=300 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

First-in-human • Monotherapy • New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck